By Will Feuer


Danaher Corp. said it expects adjusted sales to continue to rise in 2023, and indicated that it expects core revenue growth to accelerate after the current quarter.

The medical-and-diagnostics company said it expects adjusted base business core revenue, which excludes the effects of currency fluctuations as well as sales from the company's Covid-19 products, to rise by a high-single digit percent in 2023. For the current quarter, it expects the measure to rise by a mid-single digit percentage.

The company said it only issues sales guidance on an adjusted basis because of the difficulty in estimating the impact from factors like currency translation, acquisitions and divested product lines.

The guidance comes after Danaher posted better-than-expected results for the fourth quarter, driven by revenue growth in the company's life-sciences segment.


Write to Will Feuer at Will.Feuer@wsj.com


(END) Dow Jones Newswires

01-24-23 0638ET